ALN-AGT01 RVR
/ Alnylam
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 15, 2026
A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran
(clinicaltrials.gov)
- P2 | N=93 | Recruiting | Sponsor: Alnylam Pharmaceuticals | Not yet recruiting ➔ Recruiting
Enrollment open • Cardiovascular • Hypertension
1 to 1
Of
1
Go to page
1